Does the Imaging Method Have an Influence on the Measured Tumor Height in Ruthenium Plaque Therapy of Uveal Melanoma?

Schueller, Patrick; Doğan, Adnan; Panke, Joan T.; Micke, Oliver; Willich, Normann

doi:10.1007/s00066-005-1342-6

Cited by 6 publications

(11 citation statements)

References 19 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Tumor measurements are crucial for choosing adequate treatment, in particular to decide between enucleation and an eye-preserving therapy. Moreover, tumor measurements are important for the planning of the brachytherapy [3], as the plaque size used and the duration of treatment depend strongly on the size of the tumor. UM has been traditionally evaluated with ultrasound, but US tends to overestimate the tumor size [3,9].…”

Section: Discussionmentioning

confidence: 99%

“…Moreover, tumor measurements are important for the planning of the brachytherapy [3], as the plaque size used and the duration of treatment depend strongly on the size of the tumor. UM has been traditionally evaluated with ultrasound, but US tends to overestimate the tumor size [3,9]. The two important measurements that need to be taken are the tumor prominence and the largest basal tumor diameter.…”

Section: Discussionmentioning

confidence: 99%

“…This is of significant benefit to the quality of life for many patients. These eye-preserving therapies include various forms of radiotherapy, such as episcleral brachytherapy, proton-beam radiotherapy and stereotactic radiotherapy [3,4].…”

Section: Introductionmentioning

confidence: 99%

See 2 more Smart Citations

MRI of Uveal Melanoma

Ferreira

Fonk

Jaarsma-Coes

et al. 2019

Cancers

101

View full text Add to dashboard Cite

Uveal Melanoma (UM) is the most common primary malignant ocular tumor. The high soft tissue contrast and spatial resolution, and the possibility of generating 3D volumetric and functional images, make Magnetic Resonance Imaging (MRI) a valuable diagnostic imaging technique in UM. Current clinical MRI protocols, however, are not optimized for UM and therefore lack the quality for accurate assessments. We therefore developed a dedicated protocol at a 3 Tesla MRI, using an eye coil, consisting of multi-slice 2D sequences, different isotropic sequences and diffusion and perfusion-weighted images. This protocol was prospectively evaluated in 9 uveal melanoma patients. The multi-slice 2D sequences had the highest in-plane resolution, being the most suited for lesion characterization and local extension evaluation. The isotropic 3D Turbo-Spin Echo (TSE) sequences were the most suitable for accurate geometric measurements of the tumor and are therefore important for therapy planning. Diffusion and perfusion-weighted images aid in differentiating benign from malignant lesions and provide quantitative measures on tumor hemodynamics and cellularity, which have been reported to be effective in predicting and assessing treatment outcome. Overall, this dedicated MRI protocol provides high-quality imaging of UM, which can be used to improve its diagnosis, treatment planning, and follow-up.

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

MRI of Uveal Melanoma

Ferreira

Fonk

Jaarsma-Coes

et al. 2019

Cancers

101

View full text Add to dashboard Cite

show abstract

“…In support of the field of radiotherapy to implement image-guidance, the AAPM and ABS further recommend that commercial brachytherapy TPS vendors integrate tumor localization data, such as fundus photographs, 43, 102-105 ultrasonographs, 106,107 and/or CT and MRI scan images 108,109 acquired before the plaque implantation. A retinal drawing should be made that includes the tumor, centered at its clock hour and anterior-posterior location as well as its basal dimensions.…”

Section: Ivd Image-guided Brachytherapymentioning

confidence: 99%

Dosimetry of ¹²⁵I and ¹⁰³Pd COMS eye plaques for intraocular tumors: Report of Task Group 129 by the AAPM and ABS

et al. 2012

View full text Add to dashboard Cite

Dosimetry of eye plaques for ocular tumors presents unique challenges in brachytherapy. The challenges in accurate dosimetry are in part related to the steep dose gradient in the tumor and critical structures that are within millimeters of radioactive sources. In most clinical applications, calculations of dose distributions around eye plaques assume a homogenous water medium and full scatter conditions. Recent Monte Carlo (MC)-based eye-plaque dosimetry simulations have demonstrated that the perturbation effects of heterogeneous materials in eye plaques, including the gold-alloy backing and Silastic insert, can be calculated with reasonable accuracy. Even additional levels of complexity introduced through the use of gold foil "seed-guides" and custom-designed plaques can be calculated accurately using modern MC techniques. Simulations accounting for the aforementioned complexities indicate dose discrepancies exceeding a factor of ten to selected critical structures compared to conventional dose calculations. Task Group 129 was formed to review the literature; re-examine the current dosimetry calculation formalism; and make recommendations for eye-plaque dosimetry, including evaluation of brachytherapy source dosimetry parameters and heterogeneity correction factors. A literature review identified modern assessments of dose calculations for Collaborative Ocular Melanoma Study (COMS) design plaques, including MC analyses and an intercomparison of treatment planning systems (TPS) detailing differences between homogeneous and heterogeneous plaque calculations using the American Association of Physicists in Medicine (AAPM) TG-43U1 brachytherapy dosimetry formalism and MC techniques. This review identified that a commonly used prescription dose of 85 Gy at 5 mm depth in homogeneous medium delivers about 75 Gy and 69 Gy at the same 5 mm depth for specific (125)I and (103)Pd sources, respectively, when accounting for COMS plaque heterogeneities. Thus, the adoption of heterogeneous dose calculation methods in clinical practice would result in dose differences >10% and warrant a careful evaluation of the corresponding changes in prescription doses. Doses to normal ocular structures vary with choice of radionuclide, plaque location, and prescription depth, such that further dosimetric evaluations of the adoption of MC-based dosimetry methods are needed. The AAPM and American Brachytherapy Society (ABS) recommend that clinical medical physicists should make concurrent estimates of heterogeneity-corrected delivered dose using the information in this report's tables to prepare for brachytherapy TPS that can account for material heterogeneities and for a transition to heterogeneity-corrected prescriptive goals. It is recommended that brachytherapy TPS vendors include material heterogeneity corrections in their systems and take steps to integrate planned plaque localization and image guidance. In the interim, before the availability of commercial MC-based brachytherapy TPS, it is recommended that clinical medical physicists use...

show abstract

“…According to the site, tumors were classified as either juxtapapillary, macular, ciliary, or peripheral melanoma. Preoperatively, all patients underwent slit-lamp biomicroscopy, testing for best-corrected visual acuity using the Snellen chart, and echographic examination using both A and B modes of standardized ultrasound (B-Scan-S, Biovision, Clermont-Ferrand, France, or Cinescan S, Quantel Medical, Clermont-Ferrand, France) [23]. Particular dose rates were calculated by means of an in-house developed software tool according to the source certificate provided by the manufacturer.…”

Section: Introductionmentioning

confidence: 99%

Impact of Dose Rate on Clinical Course in Uveal Melanoma after Brachytherapy with Ruthenium-106

et al. 2007

View full text Add to dashboard Cite

show abstract

Does the Imaging Method Have an Influence on the Measured Tumor Height in Ruthenium Plaque Therapy of Uveal Melanoma?

Cited by 6 publications

References 19 publications

MRI of Uveal Melanoma

MRI of Uveal Melanoma

Dosimetry of ¹²⁵I and ¹⁰³Pd COMS eye plaques for intraocular tumors: Report of Task Group 129 by the AAPM and ABS

Impact of Dose Rate on Clinical Course in Uveal Melanoma after Brachytherapy with Ruthenium-106

Contact Info

Product

Resources

About

Does the Imaging Method Have an Influence on the Measured Tumor Height in Ruthenium Plaque Therapy of Uveal Melanoma?

Cited by 6 publications

References 19 publications

MRI of Uveal Melanoma

MRI of Uveal Melanoma

Dosimetry of 125I and 103Pd COMS eye plaques for intraocular tumors: Report of Task Group 129 by the AAPM and ABS

Impact of Dose Rate on Clinical Course in Uveal Melanoma after Brachytherapy with Ruthenium-106

Contact Info

Product

Resources

About

Dosimetry of ¹²⁵I and ¹⁰³Pd COMS eye plaques for intraocular tumors: Report of Task Group 129 by the AAPM and ABS